wo years in the past, AbbVie (ABBV) paid a hefty $5.eight billion to purchase a small firm with an experimental therapy for small lung most cancers, which accounts for as much as 15 % of all lung cancers. The transfer was a giant wager to increase into oncology and reduce dependence on its Humira rheumatoid arthritis medicine, an $18.four billion vendor final yr that can quickly face biosimilar competitors.
Now, although, the premise seems to be souring.
It is a STAT Plus article and you’ll unlock it by subscribing to STAT Plus at the moment. It is simple! Your first 30 days are free and when you do not get pleasure from your subscription you’ll be able to cancel any time.
Already a subscriber? Log in right here.
Pharmalot Columnist, Senior Author
Ed covers the pharmaceutical business.